drugset / Trial / NCT00403559

A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis

NCT00403559

Phase 2 Completed 113 enrolled Dermatology Specialists Research Novartis · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This is an exploratory study to determine effectiveness of Elidel for the treatment of seborrheic dermatitis

Timeline

Start
2007-05-07
Primary completion
2009-02-20
Completion
2009-02-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ketoconazole Small molecule 2 % Topical
Subject Pimecrolimus Small molecule 1 % Topical

Indications